Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intrathecal Dexmedetomidine, Adductor Canal Block, Intrathecal Dexmedetomidine + Adductor Canal Block.
- Who it may be relevant to
- Registry conditions: Intrathecal Dexmedetomidine, Adductor Canal Block, Analgesia, Total Knee Arthroplasty. Basic parameters: 18 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty: A Randomized Controlled Trial
Overview
The aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (TKA).
Detailed description
Effective postoperative pain management is essential for improving patient outcomes following knee surgery, facilitating early mobilization, and reducing the risk of complications.
The adductor canal block (ACB) is a nerve block of Hunters canal, which includes the saphenous and vastus medialis nerves. Additionally, other sensory nerves, such as the femoral nerve, medial cutaneous nerve, and both the anterior branch and terminal end of the posterior branch of the obturator nerve to some extent as it enters the distal part of the canal are blocked by the ACB.
Dexmedetomidine (DXM) a highly selective α2 adrenergic agonist with sedative, anxiolytic, analgesic, sympatholytic and antihypertensive effects.
Interventions
- Drug Intrathecal Dexmedetomidine
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery - Drug Adductor Canal Block
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery. - Drug Intrathecal Dexmedetomidine + Adductor Canal Block
Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
Primary outcome measures
- Total morphine consumption [Time frame: 48 hours postoperatively]
Secondary outcome measures (6)
- Time to the 1st rescue analgesia [Time frame: 48 hours postoperatively]
- Degree of pain [Time frame: 48 hours postoperatively]
- Heart rate [Time frame: In post-anesthesia care unit (PACU) (Up to 1 hour)]
- Mean arterial pressure [Time frame: In post-anesthesia care unit (PACU) (Up to 1 hour)]
- Degree of patient satisfaction [Time frame: 48 hours postoperatively]
- Incidence of adverse events [Time frame: 48 hours postoperatively]
Eligibility criteria
Inclusion criteria
- Age from 18 to 75 years.
- Both sexes.
- American Society of Anesthesiology (ASA) physical status I-II.
- Scheduled for total knee arthroplasty under spinal anesthesia.
Exclusion criteria
- Patients with neurological or intellectual disability.
- History of allergy to local anesthetics or dexmedetomidine .
- Infection at the injection site.
- Prolonged use of analgesic or sedative medications.
- Coagulation abnormalities.
- Pregnancy.
- Obesity \[body mass index (BMI) > 30 kg/m2\].
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Kafrelsheikh University — Kafr ash Shaykh
Identifiers
NCT: NCT06837844 · MKSU 50-1-7